Page last updated: 2024-09-05

cilengitide and Central Nervous System Neoplasm

cilengitide has been researched along with Central Nervous System Neoplasm in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H	1
Mikkelsen, T; Nabors, LB; Reardon, DA; Stupp, R	1
Tucker, GC	1

Reviews

2 review(s) available for cilengitide and Central Nervous System Neoplasm

Article	Year
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:8 Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Integrins; Models, Molecular; Oligopeptides; Protein Binding; Snake Venoms; Treatment Outcome	2008
Integrins: molecular targets in cancer therapy. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Indoles; Integrins; Melanoma; Neoplasms; Porphyrins; Skin Neoplasms; Snake Venoms; Sulfonamides	2006

Article

Year

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Expert opinion on investigational drugs, 2008, Volume: 17, Issue:8

Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Integrins; Models, Molecular; Oligopeptides; Protein Binding; Snake Venoms; Treatment Outcome

2008

Integrins: molecular targets in cancer therapy.

Current oncology reports, 2006, Volume: 8, Issue:2

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Indoles; Integrins; Melanoma; Neoplasms; Porphyrins; Skin Neoplasms; Snake Venoms; Sulfonamides

2006

Trials

1 trial(s) available for cilengitide and Central Nervous System Neoplasm

Article	Year
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. Journal of neuro-oncology, 2016, Volume: 128, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult	2016

Article

Year

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Journal of neuro-oncology, 2016, Volume: 128, Issue:1

Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult

2016